📣 VC round data is live. Check it out!
- Public Comps
- Cyclopharm
Cyclopharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cyclopharm and similar public comparables like FluoGuide, Senzime, Meta Biomed, Nexstim and more.
Cyclopharm Overview
About Cyclopharm
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
Founded
2005
HQ

Employees
95
Website
Financials (LTM)
EV
$74M
Valuation Multiples
Start free trialCyclopharm Financials
Cyclopharm reported last 12-month revenue of $24M and negative EBITDA of ($12M).
In the same LTM period, Cyclopharm generated $13M in gross profit, ($12M) in EBITDA losses, and had net loss of ($13M).
Revenue (LTM)
Cyclopharm P&L
In the most recent fiscal year, Cyclopharm reported revenue of $23M and EBITDA of ($12M).
Cyclopharm is unprofitable as of last fiscal year, with gross margin of 7%, EBITDA margin of (50%), and net margin of (52%).
Financial data powered by Morningstar, Inc.
Cyclopharm Stock Performance
Cyclopharm has current market cap of $73M, and enterprise value of $74M.
Market Cap Evolution
Cyclopharm's stock price is $0.58.
Cyclopharm share price increased by 12.3% in the last 30 days, and decreased by 31.9% in the last year.
Cyclopharm has an EPS (earnings per share) of $-0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74M | $73M | -3.6% | 12.3% | 3.9% | -31.9% | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCyclopharm Valuation Multiples
Cyclopharm trades at 3.1x EV/Revenue multiple, and (6.3x) EV/EBITDA.
EV / Revenue (LTM)
Cyclopharm Financial Valuation Multiples
As of May 16, 2026, Cyclopharm has market cap of $73M and EV of $74M.
Cyclopharm has a P/E ratio of (5.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cyclopharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cyclopharm Margins & Growth Rates
Cyclopharm grew revenue by 14% and EBITDA by 1% in the last fiscal year.
In the most recent fiscal year, Cyclopharm reported gross margin of 7%, EBITDA margin of (50%), and net margin of (52%).
Cyclopharm Margins
Cyclopharm Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Cyclopharm Operational KPIs
Cyclopharm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Cyclopharm's Rule of 40 is 73% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cyclopharm's Rule of X is 249% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Cyclopharm Competitors
Cyclopharm competitors include FluoGuide, Senzime, Meta Biomed, Nexstim, Spectral AI, Klea, Osang Healthcare, Meditera, BATM Advanced Communications and Optiscan Imaging.
Most Cyclopharm public comparables operate across Medical Devices, Medical Imaging & Diagnostics, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | (10.6x) | (9.7x) | |||
| 5.9x | 5.1x | (6.2x) | (7.9x) | |||
| 1.1x | — | 5.5x | — | |||
| 6.2x | 5.8x | 37.0x | 34.0x | |||
| 3.8x | 3.9x | (16.7x) | — | |||
| 3.5x | — | 15.5x | — | |||
| 0.9x | — | 10.4x | — | |||
| 1.1x | — | 15.6x | — | |||
This data is available for Pro users. Sign up to see all Cyclopharm competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cyclopharm
| When was Cyclopharm founded? | Cyclopharm was founded in 2005. |
| Where is Cyclopharm headquartered? | Cyclopharm is headquartered in Australia. |
| How many employees does Cyclopharm have? | As of today, Cyclopharm has over 95 employees. |
| Is Cyclopharm publicly listed? | Yes, Cyclopharm is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Cyclopharm? | Cyclopharm trades under CYC ticker. |
| When did Cyclopharm go public? | Cyclopharm went public in 2007. |
| Who are competitors of Cyclopharm? | Cyclopharm main competitors include FluoGuide, Senzime, Meta Biomed, Nexstim, Spectral AI, Klea, Osang Healthcare, Meditera, BATM Advanced Communications, Optiscan Imaging. |
| What is the current market cap of Cyclopharm? | Cyclopharm's current market cap is $73M. |
| What is the current revenue of Cyclopharm? | Cyclopharm's last 12 months revenue is $24M. |
| What is the current revenue growth of Cyclopharm? | Cyclopharm revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Cyclopharm? | Current revenue multiple of Cyclopharm is 3.1x. |
| Is Cyclopharm profitable? | No, Cyclopharm is not profitable. |
| What is the current EBITDA of Cyclopharm? | Cyclopharm has negative EBITDA and is not profitable. |
| What is Cyclopharm's EBITDA margin? | Cyclopharm's last 12 months EBITDA margin is (48%). |
| What is the current EV/EBITDA multiple of Cyclopharm? | Current EBITDA multiple of Cyclopharm is (6.3x). |
| What is the current FCF of Cyclopharm? | Cyclopharm's last 12 months FCF is ($12M). |
| What is Cyclopharm's FCF margin? | Cyclopharm's last 12 months FCF margin is (49%). |
| What is the current EV/FCF multiple of Cyclopharm? | Current FCF multiple of Cyclopharm is (6.3x). |
| How many companies Cyclopharm has acquired to date? | Cyclopharm hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Cyclopharm has invested to date? | Cyclopharm hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Cyclopharm
Lists including Cyclopharm
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.